Modification to the A11 HERV-E TCR and T cell product to improve the therapeutic efficacy for ccRCC patients.
Contract Opportunity Analysis
The National Institutes of Health, through the National Institutes of Health OLAO, is planning a non-competitive contract to modify the A11 HERV-E TCR and T cell product for improved therapeutic efficacy in patients with clear cell renal cell carcinoma. The work centers on specialized research and product modification of the A11 HERV-E TCR platform. Loyola University of Chicago is identified as the intended sole source based on its unique expertise, proprietary knowledge, and prior experience with the platform, and the acquisition is being handled under simplified acquisition procedures with performance in Bethesda, Maryland. Interested parties may submit capability statements by June 3, 2026, to Michael L. Falzone at michael.falzone@nih.gov.